Intellia Therapeutics Inc buy Royal Bank of Canada
Start price
19.09.24
/
50%
€20.95
Target price
19.09.25
€48.55
Performance (%)
-54.19%
Price
09:54
€9.60
Summary
This prediction is currently active. Massive losses of -54.19% have been the result for the BUY prediction by Royal_Bank_of_Canada. This prediction currently runs until 19.09.25. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Intellia Therapeutics Inc | -6.608% | -6.608% |
| iShares Core DAX® | 3.109% | -1.011% |
| iShares Nasdaq 100 | 3.088% | 3.918% |
| iShares Nikkei 225® | 4.760% | 5.119% |
| iShares S&P 500 | 1.840% | 2.235% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $54.00 price target on the stock.
Ratings data for NTLA provided by MarketBeat
Stopped prediction by Royal_Bank_of_Canada for Intellia Therapeutics Inc
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€9.24
08.08.25
08.08.25
€18.01
08.08.26
08.08.26
3.92%
09:54
09:54
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€19.65
09.08.24
09.08.24
€49.44
09.08.25
09.08.25
-52.65%
10.08.25
10.08.25
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€22.58
10.11.23
10.11.23
€65.49
10.11.24
10.11.24
-30.16%
11.11.24
11.11.24